Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.
A major medical problem for patients undergoing electroconvulsive therapy (ECT) is the occurrence of postictal agitation (PIA). This phenomenon is associated with confusion and disorientation that can have severe clinical implications for the safety of the patient and health care professionals. Many different pharmacological strategies have been used to prevent PIA. We present data on 40 patients who suffered from PIA after a course of ECT and evaluate the prophylactic use of orally disintegrating olanzapine in the prevention of PIA in subsequent ECT treatments.
HERMIDA, JANJUA, TANG, JOB, and McDONALD: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA SYRE: Advantage Anesthesia LLC, Atlanta, GA.
Adriana P
AP
Hermida
A Umair
AU
Janjua
Yilang
Y
Tang
Sharyn R
SR
Syre
Gregory
G
Job
William M
WM
McDonald
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology*; D001714:Bipolar Disorder / Q000628:therapy; D003865:Major Depressive Disorder / Q000628:therapy; D004565:Electroconvulsive Therapy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011595:Psychomotor Agitation / Q000209:etiology / Q000517:prevention & control*; D011618:Psychotic Disorders / Q000628:therapy; D016896:Treatment Outcome; D055815:Young Adult
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine